<?xml version="1.0" encoding="UTF-8"?>
<ref id="B105-biomolecules-09-00726">
 <label>105.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ottenlinger</surname>
    <given-names>F.M.</given-names>
   </name>
   <name>
    <surname>Mayer</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Ferreir√≥s</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Schreiber</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Schwiebs</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Schmidt</surname>
    <given-names>K.G.</given-names>
   </name>
   <name>
    <surname>Ackermann</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Pfeilschifter</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Radeke</surname>
    <given-names>H.H.</given-names>
   </name>
  </person-group>
  <article-title>Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab</article-title>
  <source>Front. Pharmacol.</source>
  <year>2016</year>
  <volume>7</volume>
  <fpage>412</fpage>
  <pub-id pub-id-type="doi">10.3389/fphar.2016.00412</pub-id>
  <?supplied-pmid 27857690?>
  <pub-id pub-id-type="pmid">27857690</pub-id>
 </element-citation>
</ref>
